Robert H. Carter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Robert H. Carter has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Alison A Moore
Department of Medicine, University of California, San Diego, San Diego, California, USA
1 shared publicationDavid M. Gray
U.S. Army Research Lab, Aberdeen Proving Ground, MD
1 shared publication- Hong Zhao
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, China
1 shared publication Jack Guralnik
Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA
1 shared publicationJames Appleby
Gerontological Society of America (GSA), Washington, District of Columbia, USA
1 shared publicationLloyd B Klickstein
Versanis Bio, Inc., Oakland, California, USA
1 shared publication
Latest Publications
- 1 June 2023
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 78 (Supplement) , 94-100
Synergistic Strategies to Accelerate the Development of Function-Promoting Therapies: Lessons From Operation Warp Speed and Oncology Drug Development
Background: Functional limitations and physical disabilities associated with aging and chronic disease are major concerns for human societies and expeditious development of function-promoting therapies is a public health priority. Methods: Expert panel discussion. Results: The remarkable success of Operation Warp Speed for the rapid development of COVID-19 vaccines, COVID-19 therapeutics, and of oncology drug development programs over the past decade have taught us that complex public health problems such as the development of function-promoting therapies will require collaboration among many stakeholders, including academic investigators, the National Institutes of Health, professional societies, patients and patient advocacy organizations, the pharmaceutical and biotechnology industry, and the U.S. Food and Drug Administration. Conclusions: There was agreement that the success of well designed, adequately powered clinical trials will require careful definitions of indication/s, study population, and patient-important endpoints that can be reliably measured using validated instruments, commensurate resource allocation, and versatile organizational structures such as those used in Operation Warp Speed.
- 1 June 2023
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 78 (Supplement) , 94-100
Synergistic Strategies to Accelerate the Development of Function-Promoting Therapies: Lessons From Operation Warp Speed and Oncology Drug Development
Background: Functional limitations and physical disabilities associated with aging and chronic disease are major concerns for human societies and expeditious development of function-promoting therapies is a public health priority. Methods: Expert panel discussion. Results: The remarkable success of Operation Warp Speed for the rapid development of COVID-19 vaccines, COVID-19 therapeutics, and of oncology drug development programs over the past decade have taught us that complex public health problems such as the development of function-promoting therapies will require collaboration among many stakeholders, including academic investigators, the National Institutes of Health, professional societies, patients and patient advocacy organizations, the pharmaceutical and biotechnology industry, and the U.S. Food and Drug Administration. Conclusions: There was agreement that the success of well designed, adequately powered clinical trials will require careful definitions of indication/s, study population, and patient-important endpoints that can be reliably measured using validated instruments, commensurate resource allocation, and versatile organizational structures such as those used in Operation Warp Speed.
- Open Access
- 1 April 2011
- Published by Elsevier in Clinical Immunology
- Vol. 139 (1) , 21-31
B lymphocytes are resistant to death receptor 5-induced apoptosis
- 1 April 2011
- Published by Elsevier in Clinical Immunology
- Vol. 139 (1) , 21-31
Open AccessB lymphocytes are resistant to death receptor 5-induced apoptosis
- 1 January 2010
- Published by ASME International
- p. 129-134
Gun Liner Emplacement Using Elastomeric Materials
The development of a process to emplace a refractory metal liner inside a gun tube is described. The process consists of filling the liner with an elastomeric material and then slipping this arrangement into the gun tube whose inner diameter is close to the outer diameter of the liner. The ends of the liner are plugged with plastic disks and pressure is applied to the elastomeric material by a load frame. This pressure can produce a residual internal stress within the steel gun tube that produces a frictional bond between the liner and gun tube. Initial efforts have resulted in bond strengths over 3 ksi (21 MPa). In addition, by tailoring the degree of lubrication between the elastomeric material and the liner, a graded autofrettage can be produced in the steel gun tube.
- 1 January 2010
- Published by ASME International
- p. 129-134
Gun Liner Emplacement Using Elastomeric Materials
The development of a process to emplace a refractory metal liner inside a gun tube is described. The process consists of filling the liner with an elastomeric material and then slipping this arrangement into the gun tube whose inner diameter is close to the outer diameter of the liner. The ends of the liner are plugged with plastic disks and pressure is applied to the elastomeric material by a load frame. This pressure can produce a residual internal stress within the steel gun tube that produces a frictional bond between the liner and gun tube. Initial efforts have resulted in bond strengths over 3 ksi (21 MPa). In addition, by tailoring the degree of lubrication between the elastomeric material and the liner, a graded autofrettage can be produced in the steel gun tube.
- 9 November 2009
- Published by Wiley
- p. 147-158
Nondestructive Evaluation of as Fabricated and Damaged Encapsulated Ceramics
- 9 November 2009
- Published by Wiley
- p. 147-158
Nondestructive Evaluation of as Fabricated and Damaged Encapsulated Ceramics
- Open Access
- 1 March 2008
- Published by Wiley in The FASEB Journal
- Vol. 22 (S1) , 847.14
B cells fail to mature or form LZ despite GC formation in CD19‐deficient mice
Germinal Centers (GC) are crucial to humoral immunity. T cells and follicular dendrtic cells (FDC) work in concert to promote antigen (Ag) specific B cell survival and maturation into antibody forming cells. CD19 is required for proper B cell activation and normal humoral responses. Therefore, we used CD19‐deficient mice to delineate the events leading to GC formation. Mice lacking CD19 do not form GC in the spleen or draining lymph nodes (DLN) in response to SRBC, and as a result, fail to activate FDC in order to receive survival signals. When wild‐type B cells were adoptively transferred into CD19‐deficient mice, GC formation and FDC activation were rescued. In contrast, GC form and FDC are activated in the mesenteric lymph nodes (MLN) of CD19‐deficient mice, presumably due to constant stimulation by Ag. Despite the presence of GC and activated FDC, GC B cells in the MLN of CD19‐deficient mice fail to downregulate IgD and CD38 compared to wild‐type GC B cells, indicating defects in maturation. Furthermore, the light zone (LZ) within these GC is almost nonexistent. Collectively, these results show that splenic and DLN FDC are inactive in CD19‐deficient mice after SBRC challenge, but despite B cell and FDC activation in the MLN of CD19‐deficient mice, CD19 is still required for GC B cells to fully mature and enter the LZ. Supported by NIH R01AI42265.
- 1 March 2008
- Published by Wiley in The FASEB Journal
- Vol. 22 (S1) , 847.14
Open AccessB cells fail to mature or form LZ despite GC formation in CD19‐deficient mice
Germinal Centers (GC) are crucial to humoral immunity. T cells and follicular dendrtic cells (FDC) work in concert to promote antigen (Ag) specific B cell survival and maturation into antibody forming cells. CD19 is required for proper B cell activation and normal humoral responses. Therefore, we used CD19‐deficient mice to delineate the events leading to GC formation. Mice lacking CD19 do not form GC in the spleen or draining lymph nodes (DLN) in response to SRBC, and as a result, fail to activate FDC in order to receive survival signals. When wild‐type B cells were adoptively transferred into CD19‐deficient mice, GC formation and FDC activation were rescued. In contrast, GC form and FDC are activated in the mesenteric lymph nodes (MLN) of CD19‐deficient mice, presumably due to constant stimulation by Ag. Despite the presence of GC and activated FDC, GC B cells in the MLN of CD19‐deficient mice fail to downregulate IgD and CD38 compared to wild‐type GC B cells, indicating defects in maturation. Furthermore, the light zone (LZ) within these GC is almost nonexistent. Collectively, these results show that splenic and DLN FDC are inactive in CD19‐deficient mice after SBRC challenge, but despite B cell and FDC activation in the MLN of CD19‐deficient mice, CD19 is still required for GC B cells to fully mature and enter the LZ. Supported by NIH R01AI42265.